You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-894-ESGO Endometrioid ovarian carcinoma – real world evidence from a large transatlantic team initiative: First results of the LEOPARD study

Article Text

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-894-ESGO Endometrioid ovarian carcinoma – real world evidence from a large transatlantic team initiative: First results of the LEOPARD study
Free
  1. Marcel Grube1,
  2. Dimtcho Batchvarov2,
  3. Koen Brummel3,
  4. Cornelis D de Kroon4,
  5. Fabienne Schochter5,
  6. Florian Heitz6,
  7. Thomas Bartl7,
  8. Sabine Heublein8,
  9. Anjali Kulkarni9,
  10. Katharina Knoll10,
  11. Alain Zeimet10,
  12. Pauline Wimberger11,12,
  13. Anna Jaeger13,
  14. Björn Lampe14,
  15. Yasmeen Amber15,
  16. Larry Phouthavongsy16,
  17. Ranjit Manchanda17,
  18. Friedrich Kommoss18,
  19. Michael S Anglesio19 and
  20. Stefan Kommoss1
  1. 1Department of Women’s Health, Tuebingen University Hospital, Tuebingen, Germany
  2. 2Department of Molecular Medicine, Université Laval, Québec, QC, Canada
  3. 3University of Groningen, Departmen of Obstetrics and Gynecology, Netherlands
  4. 4Deprtment of Gynaecology, Leiden University Medical Center, Leiden, Netherlands
  5. 5Department of Obstetrics and Gynecology, Ulm University Hopsital, Ulm, Germany
  6. 6Department of Gynecology and Gynecologic Oncology, Evangelische Kliniken Essen Mitte, Essen, Germany
  7. 7Department of Gynecology and Gynecologic Oncology, Vienna University Hospital, Vienna, Austria
  8. 8Department of Obstetrics and Gynecology, Heidelberg University Hospital, Heidelberg, Germany
  9. 9Department of Gynecologic Oncology, University of Ottawa, Ottawa, ON, Canada
  10. 10Department of Obstetrics and Gynecology, Innsbruck University Hospital, Innsbruck, Austria
  11. 11Department of Gynecology and Obstetrics, Technical University Dresden, Dresden, Germany
  12. 12National Center for Tumor Diseases, Dresden, Germany
  13. 13Department of Obstetrics and Gynecology, Hamburg University Hospital, Hamburg, Germany
  14. 14Department of Obstetrics and Gynecology, Florence Nightingale Hospital, Düsseldorf, Germany
  15. 15Division of Gynecologic Onocology, Jewish General Hospital, McGill University, Montreal, QC, Canada
  16. 16Ontaria Institute for Cancer Research, Toronto, ON, Canada
  17. 17Department of Gynecological Oncology, Barts Health NHS Trust, London, UK
  18. 18Institute of Pathology, Medizin Campus Bodensee, Friedrichshafen, Germany
  19. 19Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada

Abstract

Introduction/Background According to the WHO2020 understanding endometrioid ovarian carcinoma (ENOC) is the second most frequent ovarian carcinoma histotype. However, most historical cohorts include a significant number of misclassified cases, possibly resulting in a rather clouded picture of this histotype. We aimed to establish a large cohort of validated ENOC allowing us to study cliniocopathological characteristics and evaluate therapeutic strategies applied on an international multicentre level.

Methodology After launching a transatlantic initiative, a cohort of 846 ENOC was assembled from 22 centers across Canada and Europe after central expert pathology review and immunohistochemical validation. A detailed chart review was performed by contributing centres including surgical and adjuvant therapy data.

Results At this time a complete data set is available from 595 patients. Median age at diagnosis was 55 years (28–94). 330(55.5%) patients were diagnosed with FIGO stage I, 160(26.9%) with stage II, 77(12.9%) with stage III and 16(2.7%) with stage IV disease. Grade distribution included 238(40.2%) G1, 240(40.6%) G2 and 112(19.0%) G3 tumors. In 193(32.4%) patients a diagnosis of synchronous endometrial carcinoma was made. Surgical lymph node staging was performed in 308(51.8%) cases. Positive nodes were revealed in 26/308(8.4%) cases, of which tumor spread beyond the pelvis was described in 20/26(76.9%) patients. All low-grade tumors were node-negative. Platinum-based chemotherapy was given in 60.2% stage I, 89.1% stage II, 91.8% stage III and 86.7% stage IV patients. 5-year disease specific survival was 95.7% in stage I, 87.2% in stage II, 56.6% in stage III and 15.8% in stage IV (p<0.0001).

Conclusion We were able to assemble a large multicentre ENOC cohort. The international LEOPARD team initiative stands to provide a solid picture of this unique histotype including a powerful statement on the value of lymph-node dissection and adjuvant chemotherapy. This type-specific approach will help to improve precision care for ENOC patients.

https://doi.org/10.1136/ijgc-2022-ESGO.586

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.